An Immunohistochemical, Study Of Survivin Expression In

Normal And In Transformed Cells by Alias, Iskandar Zulkarnain
AN IMMUNOHISTOCHEMICAl, STUDY OF SURVIVIN EXPRESSION IN 
NORMAL AND IN TRANSFORMED CELLS 
by 
ISKANDAR ZULKARNAIN BIN ALIAS 
Thesis submitted in fulfillment of the 
requirements for the degree 
of Doctor of Philosophy 
SCHOOL OF MEDICAL SCIENCES 
UNIVERSITI SAINS MALAYSIA 
April 2006 
ACKNOWLEDGEMENTS 
I would like to express my gratitude to all those who have contributed to this 
work. First, I should grant my deepest appreciation and sincere thanks to my main 
supervisor, DR. FA WW AZ SHAKIR MAHMOUD AL-JOUDI for his extra-ordinary 
supervision, great help, continuous assistance, invaluable encouragement, guidance, and 
critical comments in the writing of this thesis, and support throughout my study. 
My special thanks to my co-supervisor, Mr. Imran Abdul Khaleed from 
Department of Surgery, Hospital Kota Bharu (HKB) for his assistance, and providing 
samples anddinical data for the study. Special thanks also to Dr. Ahmad Marzuki, 
from Department of Surgery, and Dr. Zakaria Jusoh, Head of Pathology Department and 
Puan Fadzlon Abu Bakar, from Department of Pathology, Hospital Kuala Terengganu 
(HKT) for providing samples. I would like to thank Associate Prof. Dr. Mustafa Musa, 
Head of Immunology Department, Associate Prof. Dr. Hasnan. Jaafar, Head of 
Pathology Department, Associate Prof Dr. Hamid Mat Sain, from Department of 
Surgery for their assistance and providing samples and also as co-researchers in USM. I 
also would like to thank Dr. Kamal Yatiban, from Department of Surgery, HUSM for 
providing me samples for the study. I would like to thank my younger brother and sister, 
Dr. Mohd. Izuddin Alias and Dr. Haslizawati Alias from Hospital Kuala Terengganu 
(HKT) for providing clinical data and assistance over there. 
My respects and thanks are due to all the staff and colleagues at the Chemical 
Pathology Department, School of Medical Sciences, USM especially to Associate Prof. 
Nor Akmal Wahab, Dr. Zulkarnain Mustafa, Encik Rafi Mustafa, and Encik Chandran 
Govindasami. I also would like to thank all the staff at the Animal House, USM 
especially to Associate Prof Dr. Afifi Sheikh Abu Bakar, Encik Maarof Saleh, Encik 
Zaini, and Encik Nor for their kindly cooperation as well as Puan Dalilati from 
Pharmacology Department, USM. I would like to thank Prof. Rani Samsuddin, the 
Dean from the School of Dental Sciences, USM who let me used the Tissue Culture 
Laboratory and all the staff in CranioFacial Laboratory especially Dr. Karima Akool AI-
Salihi, Encik Marzuki Md. Yusof, Puan Asiah Abu Bakar and Cik Fadilah Abdullah for 
their kindly cooperation. My respects and thanks also due to all the staff at the 
Pathology Department, USM, especially to Encik Rosli lusoh, Encik Ismail Abdul 
Manan, Puan Halijah Ibrahim, Puan Rushidah Yatim, and Encik Hasbullah Abdul 
Samad for their kindly high cooperation throughout the study. 
I would like to thank all the staff at the Immunology Department, School of 
Medical Sciences for their assistance especially to Puan Salwa, Puan Azma, and Puan 
Halisa. I also would like to thank Puan Zaini, The Deputy of Director from Medical 
Record Unit, HUSM for allowing me in retrieving of the medical information from the 
patients' folders from the HUSM data base. Nevertheless, gratitude is also due to the 
USM for the sponsoring the two USM Shorterm Grants (304/PPSP/613218 and 
304/PPSG/6131336). 
I also wish to thank my father, Hj. Alias bin Ab. Ghani and family, who always 
give me a moral support when I need throughout the study. I also would like to thank 
my supportive wife, Puan Anina Sari bt. Kol.(B) Hj. Ghazali (AMN), my children, 
Hafizah, Abdul Aziz, Muhammad Hafizuddin, Nur Alya Marwana, and Nur Aseela 
Ameera, who have had to put up with me working late nights and weekends to complete 
my PhD study. Finally, in hoping to get blessing from Yang Maha Esa, all the "pahala" 
comes from this thesis, I give it to my beloved mother, Allaryarham Hajjah Habsah @ 
Ramlah binti Ibrahim. This thesis is a witness of my history of life, sad and happy. 
TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS 11 
TABLE OF CONTENTS IV 
LIST OF TABLES XVlll 
LIST OF FIGURES XXI 
LIST OF PLATES XXVll1 
LIST OF PHOTOS XXXll 
LIST OF ABBREVIATIONS XXXl11 
ABSTRACT: xxxv 
ABSTRAK XXXVll 
CHAPTER I INTRODUCTION 
1.1 The cell cycle 1 
1.1.1a The normal cell cycle 1 
1.1.1b The cell cycle of tumour cell: tumour growth 3 
and cell proliferation 
1.1.2 Apoptosis 4 
1.1.2.1 The major elements of apoptosis 5 
1.1.2.2 The extrinsic apoptosis pathway 6 
1.1.2.3 The intrinsic apoptotic pathway 6 
1.1.2.4 Cell morphology and physiological 8 
changes during apoptosis 
1.1.3 Components of the apoptotic pathways 9 
1.1.3.1 The caspases death proteases 9 
1.1.3.2 Cytochrome c 10 
---
1.2 
1.3 
1.4 
1.5 
Survivin 11 
1.2.1 Structure and function of survivin 12 
1.2.2 The mechanism of survivin inhibition of 15 
apoptosis 
1.2.3 The role of survivin in cell division 16 
1.2.4 Survivin expression III cell lines, and III 16 
embryonic, fetal and normal adult tissues 
1.2.5 Survivin and cancer 18 
1.2.6 Clinical significance of survivin 20 
Bcl-2 
1.2.6.1 Prognostic value of SUrvlVIll III 21 
cancer 
1.2.6.2 Survivin as a therapeutic target III 21 
cancer 
22 
1.3.1 Structure and biological functions ofbcl-2 22 
1.3.2 Bcl-2 and its role in breast cancer 24 
1.3.3 The expression and clinical significance of bcl- 25 
2 in breast cancer 
p53 27 
1.4.1 Structure and biological functions of wild type 27 
p53 
1.4.2 Mutant p53 protein and apoptosis 28 
1.4.3 p53 pathways and its role in breast cancer 29 . 
1.4.4 The expression ofp53 in breast cancer 30 
1.4.5 The clinical significance of p53 in breast cancer 32 
Survivin, p53 and bcl-2 III breast cancer and their 
relationships 
33 
1.6 Breast cancer 33 
1.6.1 Epidemiology of breast cancer 33 
1.6.2 The normal anatomy and physiology of the 35 
breast 
1.6.3 Etiology and pathogenesis 38 
1.6.4 Risk factors 38 
1.6.5 Pathology 39 
1.6.6 Prognosis of breast cancer 40 
1.6.7 Treatment of breast cancer: Chemotherapeutic 41 
drugs 
1.6.7.1 Doxorubicin 42 
1.6.7.2 Cyclophosphamide 42 
1.6.7.3 5-Fluorouracil 43 
1.6.7.4 Tamoxifen 43 
1.6.8 Tumor markers in breast cancer 44 
1.7 Technical considerations 46 
1.7.1 Methods employed in detecting survivin 46 
1.7.2 T echnicallimitations 47 
1.8 Rationale of the study 47 
1.9 Research methodology and factors that involved in the 48 
study design 
1.10 Objectives 55 
1.10.1 The general objective 55 
1.10.2 The specific objectives 55 
"1 
CHAPTER II 
2.1 
2.2 
MATERIALS AND METHODS 56 
Experimental design 56 
Production of rabbit polyclonal antibody 56 
2.2.1 Selection criteria of peptide immunogenic sites 56 
from survivin molecule 
2.2.2 Structure of peptides 59 
2.2.3 Conjugation of peptides to keyhole limpet 62 
hemocyanin 
2.2.4 Choice of host, description and preparation of 63 
the animals 
2.2.5 Preparation for immunization of animals 
2.2.5.1 The conventional method of 
immunization 
2.2.5.2 The rapid method of immunization 
2.2.5.3 Blood withdrawal 
2.2.6 Storage of sera 
2.2.7 Antibody preparation 
63 
65 
65 
68 
68 
68 
2.2.7.1 Preparation for the polyclonal 68 
antibody purification 
2.2.7.2 Determination of IgG content III 69 
unpurified sera and purified sera 
2.2.8 SDS-P AGE 71 
2.2.8.1 Stock solutions 71 
2.2.8.2 Preparation of slab gels 72 
2.2.8.3 Preparation of samples 72 
2.2.8.4 Electrophoresis of proteins 73 
2.2.8.5 Staining and de staining of gels 73 
1.111 
2.3 
2.2.8.6 Electrophoretic transfer, 
immunoblotting, and preabsorption 
test 
2.2.8.6a Western transfer 
2.2.8.6b Staining of transferred proteins 
2.2.8.6c Immunoblotting 
2.2.8.7 Preabsorption test 
The immunohistochemistry assay 
74 
74 
77 
77 
78 
79 
2.3.1 Preparation of tissue blocks and tissue fixation 79 
2.3.1.1 Tissue processing 79 
2.3.1.2 Poly-L-Iysine slides 80 
2.3.1.3 Tissue embedding, sectioning and 81 
fishing 
2.3.2 Haematoxylin and Eosin Staining 81 
2.3.3 Preparation of immunohistochemical staining 82 
for survivin 
2.3.3.1 Antigen retrieval method 
development and the immunoassay 
2.3.3.2 Chequerboard analysis 
82 
82 
2.3.3.2.1 Staining by primary and 83 
secondary antibodies 
2.3.3.2.1a Selection and testing a 84 
series of pnmary 
antibody dilutions 
2.3.3.2.1b Selection and testing a 84 
series of secondary 
antibody dilutions 
2.3.3.3 The scoring system for survivin 
expression 
"{T111 
85 
2.4 
2.5 
2.6 
Investigations of survivin expression in breast cancer 
cell line, MCF-7 
86 
2.4.1 Cell line selection and cell cultivation 86 
2.4.2 Maintenance of established cellular growth and 86 
harvesting of cells 
2.4.3 Preparation of chemotherapeutic drugs 87 
2.4.4 Cell counting and evaluation of viable cells 87 
2.4.5 Tumor cell inhibition assays 88 
2.4.6 The apoptosis assay 89 
2.4.6.1 Detection and quantification of 
apoptosis 
2.4.6.2 Apoptotic index 
2.4.7 Immunocytochemistry 
2.4.7.1 Immunocytochemistry assay 
2.4.7.2 Scoring system for survivin 
expression 
Investigation of SurvlVIll expression III fetuses, and 
normal adult animal tissues 
89 
90 
90 
90 
91 
92 
2.5.1 Preparation of pregnant animals 92 
2.5.2 Preparation of mouse fetuses, and adult 93 
tissues for survivin staining 
2.5.3 Immunohistochemical staining for the detection 94 
of survivin in animal tissues 
Survivin expression in breast cancer tissues: a clinical 
survey 
2.6.1 Study design and sample size 
2.6.1.1 Patients selection and parameters 
2.6.1.2 Sample size 
2.6.1.3 Inclusion criteria 
tv 
94 
94 
94 
95 
95 
2.6.2 Clinicopathological defmitions 96 
2.6.3 Immunohistochemistry for survivin detection 96 
2.6.4 Preparation of immunohistochemical staining 97 
for p53 and bcl-2 
2.6.4.1 Immunostaining for p53 97 
2.6.4.2 Immunostaining for bcl-2 97 
2.6.5 Viewing and interpretation of survivin, p53, 98 
and bcl-2 results on slides 
2.7 Detection of anti-survivin autoantibodies 98 
2.7.1 Sera 98 
2.7.2 ELISA 99 
2.8 Statistical analyses 100 
CHAPTER III PRODUCTION AND STANDARDIZATION OF 101 
IMMUNOHISTOCHEMISTRY A8SA Y 
3.1 Introduction 101 
3.1.1 Polyclonal antibody production 101 
3.1.2 Rationale of the production of anti-survivin 103 
polyclonal rabbit antibody 
3.2 Results 104 
3.2.1 Concentration of IgG in different polyclonal 104 
anti-sera 
3.2.2 Specificity of the antibodies 105 
3.2.2.1 Western blotting 105 
3.2.2.2 Preabsorption test 108 
3.2.3 Standardization of the immunohistochemistry 109 
assay 
,~. 
3.3 
3.4 
3.2.3.1 Development of a procedure for 109 
antigen retrieval 
3.2.3.2 Selecting the optimum polyclonal 116 
rabbit anti-survivin serum for IRC 
assay 
3.2.3.3 Comparing the conventional method 116 
and the rapid method of 
immunization 
3.2.3.4 Comparing sera and purified 116 
antibody products 
3.2.3.5 Chequerboard analysis for the 
selected pnmary and secondary 
antibodies 
117 
3.2.3.5a Determination of the optimal titers 118 
for indirect immunoperoxidase 
method for SURI2A- RFI 
3.2.3.5b Detennination of the optimal titers 
for indirect immunoperoxidase 
method for SURI2A- CFI 
3.2.3.6 Validation of immunohistochemical 
assay 
122 
126 
Discussion 127 
3.3.1 Selection of sequences and specificities 127 
3.3.2 Development of an immunohistochemistry 129 
assay 
3.3.3 Antigen retrieval method development 132 
3.3.4 Validation of the assay 133 
3.3.5 Technical considerations 133 
Conclusions 136 
V1 
CHAPTER IV SURVIVIN EXPRESSION IN FETAL AND ADULT 137 
4.1 
4.2 
-,::' 
4.3 
NORMAL TISSUES OF MOUSE AND RAT 
Introduction 137 
4.1.1 Homologues ofsurvivin 139 
4.1.2 Function of survivin m embryonic, fetal 140 
development and tissue differentiation 
4.1.3 Rationale of study 141 
Results 
4.2.1 Overall fetal body expreSSIOn and organ 
expression of survivin 
142 
142 
4.2.2 Expression of survivin in mouse fetus 148 
4.2.3 Expression of survivin in selected organs of 150 
adult normal tissues of rat 
Discussion 152 
4.3.1 Expression of survivin in animal tissues 152 
4.3.2 Subcellular localization of survivin 153 
4.3.3 Structural homology of human, rat and mouse 153 
survlvm 
4.4 Conclusions 154 
CHAPTER V THE EFFECTS OF CHEMOTHERAPEUTIC DRUGS 155 
ON CELL VIABILTY, APOPTOSIS, AND SURVIVIN 
EXPRESSION IN MCF -7 CELLS 
5.1 Introduction 155 
5.1.1 Morphology and characteristics of the breast 156 
cancer cellline, MCF-7 
5.1.2 The effect of chemotherapeutic drugs on 156 
apoptosis 
Vl1 
\::' 
5.3 
5.4 
5.1.3 Rationale of the study 158 
5.2 Results 159 
5.2.1 Cell viability 159 
5.2.2 ICso estimation 159 
5.2.2.1 The effect of doxorubicin on cell 160 
viability of MCF-7 
5.2.2.2 The effect of cyclophosphamide on 161 
cell viability of MCF-7 
5.2.2.3 The effect of 5-FU on cell viability of 162 
MCF-7 
5.2.2.4 The effect of TAM on cell viability 
ofMCF~7 
163 
5.2.3 The effect of drugs inducing apoptosis 164 
5.2.4 The intensity of the survivin expression III 168 
MCF-7 cell line 
5.2.5 The subcellular localization of survivin: 169 
effects of chemotherapeutic drugs 
Discussion 175 
5.3.1 The effect of chemotherapeutic drugs on cell 175 
viability 
5.3.2 The effect of chemotherapeutic drugs on 176 
SurvlVIll expreSSIOn and its subcellular 
localization 
5.3.3 The effect of chemotherapeutic drugs on 178 
apoptosis 
Conclusions 180 
CHAPTER VI SURVIVIN EXPRESSION AND ITS SUBCELLULAR 181 
LOCALIZATION IN INFILTRATING DUCTAL 
CARCINOMA OF THE BREAST AND ITS 
RELATIONSHIP WITH CLINICOPATHOLOGICAL 
FACTORS, HORMONAL STATUS, P53 AND BCL-2 
6.1 Introduction 181 
6.2 
6.1.1 Rationale of the study 182 
Results 184 
6.2.1 Patients demographics 184 
6.2.1.1 a The overall distribution of cases 184 
according to age group 
6.2.1.1 b The incidence of infiltrating ductal 186 
carcinoma of the breast in different 
age group according to the 
histopathological grade 
6.2.1.2 The overall distribution of the cases 187 
according to the ethriic group 
6.2.1.3 The overall distribution of cases 188 
according to the tumour size range 
6.2.1.4 The overall distribution of cases 189 
according to the tumour side 
6.2.1.5 The overall distribution of cases 190 
according to the lymph node status 
6.2.1.6a The overall distribution of cases 191 
according to the tumour histological 
grade 
6.2.1.6b The distribution of age, tumour size, 192 
ER, PR, p53,bcl-2, and SurvlVlll 
according to tumour histological 
grade 
6.2.2 The expression of survivin and its correlation 194 
with the clinicopathological factors and 
honnonal status in infiltrating ductal carcinoma 
ofthe breast 
V1'tT 
6.2.3 The expression of p53 and its correlation with 197 
clinicopathological factors and honnonal status 
in infiltrating ductal carcinoma of the breast 
6.2.4 The expression ofbcl-2 and its correlation with 201 
clinicopathological factors, and honnonal status 
in infiltrating ductal carcinoma of the breast 
6.2.5 The correlation between survivin, p53, and bcl- 205 
2 among the subjects 
6.2.5.1 Correlation between survivin and p53 205 
expression 
6.2.5.2 Correlation between SurvlVlll and 206 
bcl-2 expression 
6.2.5.3 Correlation between p53 and bcl-2 
expreSSIOn 
207 
6.2.6 The overall subcellular survivin expression 208 
among the survivin positive cases in infiltrating 
ductal carcinoma of the breast 
6.2.6.1 The distribution and correlation of 209 
subcellular survivin expression with 
tumour size range 
6.2.6.2 The distribution and correlation of 210 
subcellular survivin expression with 
tumour grade 
6.2.6.3 The distribution and correlation of 211 
subcellular survivin expression with 
tumour side 
6.2.6.4 The distribution and correlation of 212 
subcellular survivin expression with 
lymph node status 
6.2.6.5 The distribution and correlation of 213 
subcellular survivin expression with 
the estrogen receptor status 
6.2.6.6 The distribution and correlation of 214 
subcellular survivin expression with 
the progesterone receptor status 
YV 
6.3 
6.4 
6.2.6.7 The distribution and correlation of 215 
subcellular survivin expression with 
p53 expression 
6.2.6.8 The distribution and correlation of 216 
subcellular survivin expression with 
bcl-2 expression 
6.2.7 The correlation between the outcome of the ·217 
patients with survivin expression 
6.2.8 Multiple regression test to see the influence of 219 
independent factors on the outcome variable 
(dependant factor) 
6.2.9 Prognostic analysis in patients with IDC of the 
breast 
Discussion 
221 
222 
6.3.1 Patients characteristics 222 
6.3.2 The expreSSIOn of survlvm among the 225 
infiltrating ductal carcmoma of the breast 
patients 
6.3.3 The correlation between the clinicopathological 225 
factors, hormonal status and survivin, p53, and 
bcl-2 expression 
6.3.4 Correlation between survivin, p53 and bcl-2 226 
expreSSIOn 
6.3.5 Survivin expression as a diagnostic and a 
prognostic indicator 
6.3.6 Subcellular localization of survivin and its 
prognostic factor 
Conclusions 
229 
230 
233 
CHAPTER VII DETECTION OF AUTOANTIBODIES TO 234 
SURVIVIN IN INFILTRATING DUCTAL 
CARCINOMA OF THE BREAST PATIENTS SERA 
7.1 Introduction 234 
7.1.1 Rationale of the study 235 
7.2 Results 236 
7.2.1 Detection of anti-survivin autoantibodies by 236 
indirect ELISA 
7.3 Discussion 239 
7.4 Conclusions 241 
,t;' 
CHAPTER VIII GENERAL DISCUSSION 242 
CHAPTER IX CONCLUSIONS and FUTURE DIRECTIONS 249 
REFERENCES 
APPENDICES 
Appendix 1 
Appendix 2 
Appendix 3 
Appendix 4 
Appendix 5 
Appendix 6 
Appendix 7 
Consent Letter 
Data Collection Form 
WHO Histological Classification of Breast 
Tumour (1981) 
Microscopic Grading of Breast Carcinoma: 
Nottingham Modification of the Bloom-
Richardson System 
Protocol for blood and tissue collections 
Examples of Histopathological report from 
HUSM, HKB, and HKT 
List of Publications 
251 
299 
303 
309 
311 
312 
313 
314 
Table 
1.1 
1.2 
1.3 
1.4 
2.1 
2.2 
2.3 
2.4 
3.1 
3.2 
3.3 
3.4 
3.5 
LIST OF TABLES 
Title 
Meta analysis of survivin expression III cancers III 
published reports 
Meta analysis of bcl-2 expression in breast cancer in 
published reports 
Meta analysis of p53 expression in breast cancer patients 
in published reports 
Meta analysis of different technique III SurvlVIll 
detection in different studies using different types of 
specimens from previous studies 
List of anti-survivin antibodies produced by several 
authors and companies and their selected surviviii 
amino peptide sequence as a source of infonnation for the 
present study 
Recipes for SDS-P AGE preparation 
Profile of tissues processing steps for brea~t cancer 
samples 
Design of chequerboard analysis 
The names of four different types of polyclonal rabbit 
anti-survlvIll sera produced by two different 
immunization protocols in this study 
Estimation of concentration of total proteins (mg/ml) and 
IgG (mg/ml) in different polyclonal rabbit anti-survivin 
sera 
The staining intensity of survivin in breast and colon 
cancer tissue sections according to the types and the pH of 
antigen retrieval buffer 
Detennination of optimal titers for indirect 
immunoperoxidase method for SURI2A-RFI antibody 
with antigen retrieval buffer Tris-EDT A, pH 9 
Determination of optimal titers for indirect 
immunoperoxidase method for SUR12A-CFI antibody 
with antigen retrieval buffer Tris-EDTA, pH 9 
Page 
19 
26 
31 
46 
61 
72 
80 
85 
104 
105 
111 
118 
122 
5.1 
6.1 
6.2 
6.3 
6.4 
6.5·, 
6.6 
6.7 
6.8 
6.9 
6.10 
6.11 
6.l2 
6.13 
The intensity of the survivin expression in the MCF-7 cell 168 
line after treatment with the chemotherapeutic drugs 
The dlstribution of age, tumour size, survivin, p53, bcl-2, 193 
ER, PR, and lymph node metastasis according to tumour 
histological grade 
The correlation between clinicopathologic factors and 196 
expression of survivin in breast cancer 
The correlation between clinicopathologic factors and 200 
expression ofp53 in breast cancer 
The correlation between clinicopathologic factors, 204 
honnonal status, and expression ofbcl-2 in breast cancer 
The correlation between survivin and p53 in infiltrating 205 
ductal carcinoma of the breast 
The correlation between survivin and bcl-2 in infiltrating 206 
ductal carcinoma of the breast patients 
The correlation between p53 and bcl-2 ill infiltrating 207 
ductal carcinoma of the breast patients 
The distribution of subcellular localization of survivin 209 
among the survivin positive infiltrating ductal carcinoma 
of the breast according to the tumour size range 
The distribution of subcellular localization of survivin 
among the survivin positive infiltrating ductal carcinoma 
of the breast according to the tumour grade 
The distribution of subcellular localization of survivin 
among the survivin positive infiltrating ductal carcinoma 
of the breast according to the tumour side 
The distribution of subcellular localization of survivin 
among the survivin positive infiltrating ductal carcinoma 
of the breast according to the lymph node status 
The distribution of subcellular localization of survivin 
among the survivin positive infiltrating ductal carcinoma 
of the breast according to the estrogen receptor status 
The distribution of subcellular localization of survivin 
among the survivin positive infiltrating ductal carcinoma 
of the breast according to the progesterone receptor status 
210 
211 
212 
213 
214 
6.14 
6.15 
6.16 
,';' 
The distribution of subcellular localization of survivin 
among the survivin positive infiltrating ductal carcinoma 
of the breast according to p53 expression 
The distribution of subcellular localization of survivin 
among the survivin positive infiltrating ductal carcinoma 
of the breast according to the bcI-2 status 
Multiple regression "Forward Stepwise" to see the 
influence of other factors on the outcome alive or dead 
215 
216 
219 
Figure 
1.1 
1.2 
1.3 
1.4 
1.5 
1.9.1 
1.9.2 
1.9.3 
1.9.4 
2.1 
LIST OF FIGURES 
Title 
Cell cycle pathways showing its check points and 
regulators of a nonnal cell. M=Mitosis, G= Gap, 
S=Synthesis, R==Restriction (Andreeff et at., 2000; 
Li et al., 1998) 
The routes of apoptosis (Reed, 2001; Bomer, 2003; 
Bossy-Wetzel & Green, 1999; Suzuki et at., 2001; 
Coultas & Strasser, 2003) 
The overall architecture of human survivin. a, Ribbon 
representation of the survivin dimer. The Zn 2+ ion is 
shown as a shaded sphere. Coordination bonds are shown 
as dotted orange spheres. One monomer is blue; the other 
is rose. b, Orthogonal view of the ribbon representation 
shown in (a).c, Perspective and close up view of the Zn2+ 
binding site on one survivin monomer. The depicted 
orientation corresponds to that pictured in (a). (Verdecia 
et at., 2000) 
Anatomy of nonnal female breast (Source: 
http://www.diasus.com) 
Anatomy of nonnal female breast with axillary lymph 
nodes (Source: http://www.slp-hormones.co.uk) 
Flowchart of development of immunochemical assay for 
detection of survivin in a variety of tissues 
Flowchart of investigations of survivin expression III 
selected normal fetal and adult tissues in rat and mouse 
Flowchart of investigation of the effect of different doses 
of selected chemothrerapeutic drugs on the relative cell 
viability, apoptosis, and subcellular localization of 
survivin expression in the human breast cancer cell line, 
MCF-7 
Flowchart of clinical investigation of survivin expression 
in human breast cancer 
Flowchart of methodology of polyc1onal antibody 
production 
Page 
2 
7 
14 
37 
37 
51 
52 
53 
54 
57 
2.2a 
2.2b 
2.2c 
2.3 
2.4 ," 
2.5 
3.1a 
3.1b 
3.2 
Survivin molecule and the location of selected peptide in 58 
the molecule as a antigenic detenninants 
A) Survivin-like polypeptide and its DNA (426 bp). B) 59 
Confinnation of the human survivin polypeptide sequence 
(GeneBank Accession No. AAC51660). The underlined 
sequences were the survivin amino sequences used to 
produce the peptides 
Peptide hydrophilicity analysis by using Epitope Software 60 
Analysis (Source: http://www.innovagen.se/custom-
peptide-synthesis/peptide-property -calculator/peptide-
property-calculator.asp 
Schedule of conventional immunization protocol for . 66 
polyc1onal rabbit antiserum antibody production in rabbits 
Schedule of rapid immunization protocol for polyc1onal 67 
rabbit antiserum antibody production in rabbits 
Transfer sandwich and Multiphor II NovaBlot Unit for 76 
electrophoretic transfer 
(A) The SDS-P AGE of whole breast cancer tissue lysate 106 
in gel and (B) The completely Western blotting transfer 
onto PVDF membrane stained withamido black. 
The Western blot analysis showing the specific 107 
immunoreactivity of antibodies to survivin on PVDF 
membrane. A) Two markers bands (arrows) stained with 
Amido Black B) Western blot with the preimmunized 
sera showed no immunoreactivity (no band) C) Western 
blot analysis against total protein extract from breast 
cancer tissue lysate showed reactivity with a single band 
of protein at approximately 16.5 kd, consistent with the 
expected molecular weight with polyc1onal serum 
antibody, SUR12A-RFI D) Band of survivin in breast 
cancer tissue lysate stained with polyc1onal serum 
antibody, SUR12A-CFI. E) Western blot with nonnal 
breast tissue lysate, no immunoreactivity 
The plates of chequerboard titration of primary antibody 119 
SURI2A-RFI in fixed dilution of secondary antibody 
(1:160) colon cancer tissue sections. (Panel A) ISS +3, 
NSB (+3), Dilution: 1: 5 (Panel B) ISS +3, NSB (+3), 
Dilution: 1: 20 (panel C) ISS +3, NSB (+2 ), Dilution: 
1: 80 (Panel D) ISS +3, NSB (+2 ), Dilution: 1: 320 
(Panel E) ISS +3, NSB (+2) Dilution: 1: 1280 (Panel F) 
ISS (0), NSB (0), Negative control : with preimmune 
rabbit sera (Original magnification X 400). (188=. 
Intensity specific staining; NSB = nonspecific 
background) 
3.3a The chequerboard titration of primary Ab SURI2A-RFI 120 
in fixed dilution of secondary Ab 1: 40 
3.3b The chequerboard titration of primary Ab SURI2A-RFI 120 
in fixed dilution of secondary Ab (1: 80) 
3.3c The chequerboard titration of primary Ab SURI2A-RFI 121 
in fixed dilution of secondary Ab 1:160 
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SURI2A-CFI in fixed dilution of secondary antibody 
(1:160) colon cancer tissue sections (Panel A) ISS +3, 
NSB (+3) Dilution: 1: 5) (panel B) ISS +3, NSB (+3), 
Dilution: 1: 20 (Panel C) ISS +3, NSS (+2), Dilution: 
1: 80 (panel D) Intensity of specific staining +3, Non-
specific background (+2), Dilution: 1: 320 (Panel E) ISS 
+3, NSB(1+), 1: 1280) (Panel F) ISS (0), NSS (0) 
Negative control : with preimmune rabbit sera (Original 
magnification X 400).(ISS= Intensity specific staining, 
NSB= non-specific background 
3.5a The chequerboard titration of priI)1ary Ab SUR)2A-CFI 124 
in fixed dilution of secondary Ab (1: 40). 
3.5b The chequerboard titration of primary Ab SUR12A-CFI 124 
in fixed dilution of secondary Ab (1: 80) 
3.5c The chequerboard titration of primary Ab SUR12A-CFI 125 
in fixed dilution of secondary Ab (1: 160). 
4.1 Human, mouse and rat apoptosis inhibitor survivin amino 139 
sequence. The sequences used to produced SUR12A-CFI 
as in bold text (Ambrosini et aI., 1997; Uren et aI., 2001; 
Kobayashi et at., 1998) 
4.3 Plates showing the positive immunostaining of survivin in 149 
the liver during fetal development of mouse at day 18. 
Panel A) Original magnification x 2.5 Panel B) Arrows 
show the cytoplasmic staining of survivin (Original 
magnification x400) 
5.1 a The effect of different concentration of doxorubicin on 160 
the relative viability of MCF-7 cell line after 72 hours. 
Each value represents the mean ± s.d. of four independent 
triplicate experiments. Percentage values of cell viability 
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was obtained with untreated control cells maintained 
under identical experimental conditions were taken as 
100%. 
The effect of different concentration of cyclophosphamide 
on the relative viability of MCF-7 cell line after 72 hours. 
Each value represents the mean ± s.d. of four independent 
triplicate experiments. Percentage values of cell viability 
was obtained with untreated control cells maintained 
under identical experimental conditions were taken as 
100%. 
The effect of different concentration of 5-fluorouracil on 
the relative viability of MCF -7 cell line after 72 hours. 
Each value represents the mean ± s.d. of four independent 
triplicate experiments. Percentage values of cell viability 
was obtained with untreated control cells maintained 
tmder identical experimental conditions were taken as 
100% 
The effect of different concentration of tamoxifen on the 
relative viability of MCF-7 cell line after 72 hours. Each 
value represents the mean ± s.d. of four independent 
triplicate experiments. Percentage values of cell viability 
was obtained with untreated control cells maintained 
under identical experimental conditions were. taken as 
100% 
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5.2 Micrographs showing examples of the morphological 165 
changes and evidence of apoptosis in MCF-7 cells after 
72 hours in the presence of chemotherapeutic drugs. Panel 
A) Showing apoptostic bodies after staining with acridine 
orange and propidium iodide flourescent dyes, red colour 
at late apoptosis stage (white arrow) and also can be seen 
are a few cells in an early stage of apoptosis (blue arrow). 
Panel B) Showing the MCF-7 cells with no evidence of 
apoptosis. These microphotographs were taken using a 
Confocal Laser Microscope (Zeiss) 
5.3a Spontaneous and doxorubicin-induced apoptosis in MCF- 166 
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5.3b Spontaneous and cyclophosphamide-induced apoptosis in 166 
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Example of micrographs showing the expression of 
survivin in the human breast cancer cel11ine MCF-7 after 
incubation with chemotherapeutic drug. Plate A) Original 
magnification x 100, intensity (+++). Plate B) Original 
magnification x400, intensity (+++). Most of the cells 
expressed predominantly cytoplasmic staining (C>N) and 
only a small percentage of cells showed nuclear-
cytoplasmic (N/C) and exclusively cytoplasmic (C) 
staining of survivin. There was no predominantly nuclear 
(N)C) staining. The score values in the experiment was 
performed by the specific standard scoring system 
The effect of doxorubicin on the subcellular localization 
of survivin. The localization of the survivin within a cell 
was classified as predominantly nuclear (N)C), nuclear 
and cytoplasmic (N/C), predominantly cytoplasmic 
(C>N), or exclusively cytoplasmic (C). The bars represent 
the mean of four independent experiments with less than 
10% variation. More than 1000 cells were counted per 
experiment according to 5, 1, 0.5, 0.2, 0.1 x PPC. The 
PPC of doxorubicin is 0.5 f.Lg/ml. Most of the cells 
expressed cytoplasmic staining and only a small 
percentage expressed nuclear-cytoplasmic staining 
The effect of cyclophosphamide on the subcellular 
localization of survivin. The localization of the survivin 
within a cell was classified as predominantly nuclear 
(N)C), nuclear and cytoplasmic (N/C), predominantly 
cytoplasmic (C>N), or exclusively cytoplasmic (C). The 
bars represent the mean of four independent experiments 
with less than 10% variation. More than 1000 cells were 
counted per experiment according to 5, 1, 0.5, 0.2, 0.1 x 
ppc. The PPC of doxorubicin is 6 f.Lg/ml. Most of the 
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The effect of 5-FU on the subcellular localization of 
survivin. The localization of the survivin within a cell was 
classified as predominantly nuclear (N)C), nuclear and 
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exclusively cytoplasmic (C). The bars represent the mean 
of four independent experiments with less than 10% 
variation. More than 1000 cells were counted per 
experiment according to 5, 1, 0.5, 0.2, 0.1 x PPC. The 
PPC of doxorubicin is 60 f.Lg/ml. Most of the cells 
expressed cytoplasmic staining and only a small 
percentage expressed nuclear-cytoplasmic staining 
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A micrograph showing the immunostaining of survivin 
( arrows) scoring ++( ++), and in category 3 of positivity 
in breast cancer tissue section with antigen retrieval buffer, 
citrate buffer, pH 6 with dilution of primary SUR12A-CFI 
antibody 1: 1280 and secondary antibody dilution 1: 160 
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(arrows) scoring +++ (+), and in category 4 of positivity 
in breast cancer tissue section with antigen retrieval buffer 
Tris-EDTA pH 9, with dilution of primary SUR12A-CFI 
antibody 1: 1280 and secondary dilution antibody 1: 160 
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Note: +++ (+) = intensity of specific staining (intensity of 
background staining). A mean percentage of positive 
tumor cells was determined in at least five areas at X 400 
magnification and assigned to one of the five following 
categories: (a) 0, < 5%; (b)l, 5-25%; (c)2, 26-50%, (d) 3, 
51-75%; and (e) 4, > 75%. The intensity of survivin 
immunostaining was scored as follows: (a) weak, +; (b) 
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A micrograph showing the internal negative control of 
breast cancer tissues section scoring 0 (0) with citrate 
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A micrograph showing the immunostaining of survivin 
(arrows) with scoring +++ (+), and in category 3 of 
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moderate, ++; (c) intense, +++. 
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categories: (a) 0, < 5%; (b)l, 5-25%; (c)2, 26-50%, (d) 3, 
51-75%; and (e) 4, > 75%. The intensity of survivin 
immunostaining was scored as follows: (a) weak, +; (b) 
moderate, ++; (c) intense, +++ 
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AN IMMUNOHISTOCHEMICAL STUDY OF 
SURVIVIN EXPRESSION IN NORMAL AND IN TRANSFORMED CELLS 
ABSTRACT 
Survivin is a new member of the inhibitors of apoptosis protein (IAP) family, selectively 
over-expressed in common human cancers but not in normal adult tissues. It is also 
expressed in cancer cell lines. The study was performed generally to investigate the 
basic and clinical roles of survivin in normal and transformed cells. Rabbits were 
immunized with two synthetic oligopeptides, MGAPTLPP A WQP and 
KEFEET AKKVRRAIEQLAAMD amino acids sequences of the survivin molecule. 
Serum antibodies were purified by ammonium sulphate and caprilic acid and their 
specificities were confirmed by immunoblo~ing and pre-absorption tests against 
survivin positive tissues or synthetic survivin oligopeptides. These antibodies were used 
to detect survivin in normal and transformed cells by immunohistochemistry in 
formalin-fixed paraffin embedded tissue sections, evaluated by a standard scoring 
system and chequerboard analysis. Normal cells were obtained frqm fetal and adult 
tissues of mouse and rat whilst the transformed cells were obtained from the human 
breast cancer cell line MCF-7 and the infiltrating ductal carcinoma (IDC) of the breast 
patients. In the MCF-7 cell line experiment, the effects of chemotherapeutic drugs 
namely doxorubicin, 5-fluorouracil, cyclophosphamide, and tamoxifen on the apoptosis 
index measured by propidium iodide and acridine orange dyes. The relative cell viability 
was measured by an MTT assay and survivin expression was measured by 
immunocytochemistry. In IDC patients (n=382), survivin expression in tissues was 
analyzed for its correlation with clinicalpathological factors, hormonal status, p53, bcl-2 
and the survival rate. Patients and their tissue blocks were obtained from three general 
hospitals in The East Coast of Malaysia. Autoantibodies to survivin were also 
investigated in the sera of the same IDC patients population (n=57) and were compared 
to the control population (n=44). For the immunohistochemistry assay, four rabbit 
antiserum were produced and tested against survivin. The results of this study indicated 
that the antigen retrieval buffer, pH 9 was superior than pH 6 and optimization 
immunohistochemistry was obtained by chequerboard analysis. Furthermore, it was 
found that survivin is expressed abundantly in normal growing fetal cells but not in 
normal differentiated adult tissues of mouse and rat. In the MCF-7 cell line, the cell 
viability was reduced in a dose-dependent pattern when incubated with the drugs. The 
ICso estimation in MCF-7 cell line for doxorubicin was 6.0 Ilg/ml, cyclophosphamide 
171.1 Ilg/ml, 5-fluorouracil 0.611lg/ml, and tamoxifen 0.71lg/ml, respectively. It was 
found that most of the MCF-7 cells expressed survivin, predominantly in the cytoplasm. 
The percentages of apoptotic celli; were increased with the increased concentrations of 
the drugs. Among the IDe patients, the expression of survivin was 68.1 %, p53 29.6%, 
and bcl-2 43.7%, respectively. There was a significant correlation (p<0.05) between 
survivin expression and lymph node involvement, tumour sizes, p53, bcl-2 expression, 
and survival rate among the IDC patients. Anti-survivin autoantibodies reactivities were 
detected in 7% of the sera of IDC patients but not in normal sera. These autoantibodies 
correlated with the positivity of survivin expression, and with advanced breast cancer. It 
was concluded that survivin was abundantly and prominently expressed during fetal 
development of rat and mouse. The polyclonal antibody SUR12A-CFI recognized rat 
and mouse survivin. It was also concluded that survivin is frequently over-expressed in 
IDC patients, and in most MCF-7 cells. Survivin expression has a predictive value in 
predicting the aggressiveness of the tumour cells suggesting that survivin may be a 
useful tool in assessing a prognosis. 
KAJIAN IMUNOmSTOKIMIA 
TERHADAP EKSPRESI SURVIVIN DI 
DALAM SEL NORMAL DAN SEL TERTRANSFORMASI 
ABSTRAK 
Survivin merupakan ahli barn dalam keluarga protin perencat apoptosis, secara terpilih 
diekspres secara berlebihan dalam kebanyakan kanser tetapi tidak di dalam tisu dewasa 
nonnaL Ia juga diekspres di dalarn rangkaian sel-sel kanser. Kajian ini dilakukan bagi 
mengkaji secara asas dan klinikal tentang survivin di dalam sel normal- dan sel 
tertransfonnasi. Amab telah diirnunkan dengan sintetik oligopeptida, jujukan asid 
amino, MGAPTLPP A WQP dan KEFEET AKKVRRAIEQLAAMD daripada molekul 
survivin. Antibodi serum ditulenkan dengan ammonium sulfat dan asid caprilik dan 
speksifikasinya telah disahkan dengan teknik imrnunoblot dan ujian penyerapan awal 
terhadap tisu positif survivin dan sintetik oligopeptidasurvivin. Antibodi ini telah 
digunakan untuk -rnengesan survivin di dalam sel nonnal dan sel tertransfonnasi 
menggunakan kaedah imunohistokirnia pada hirisan tisu fonnalin-paraffm dan diukur 
menggunakan kaedah sistern pengskoran piawai dan analisis optimasi. Sel nonnal 
diperolehi daripada tisu fetus dan tisu dewasa tikus dan rnencit rnanakala sel 
tertransformasi diperolehi daripada rangkaian sel kanser payu dara MCF-7 dan pesakit 
karsinoma infiltrasi kalenjar payu dara. Di dalam kajian rangkaian sel MCF-7, kesan 
dadah kernoterapi iaitu Doxorubicin, 5-Fluorourasil, Cyclophosphamide dan Tarnoxifen 
ke atas indek apoptosis yang diukur dengan kaedah propidiurn iodida dan akridin oren. 
Relatif sel viabiliti diukur dengan ujian MIT dan ekspresi survivin diukur dengan 
kaedah imrnunositokirnia. Korelasi antara faktor klinikopatologi, status honnon, p53, 
bcl-2 dan kadar hidup di kalangan pesakitr kanser payu dara (n=382) telah dianalisa. 
Blok-blok tisu daripada pesakit telah diperolehi daripada tiga hospital utama di Pantai 
Timur. Autoantibodi terhadap survivin juga telah dikaji di dalam serum pesakit kanser 
payu dara (n=S7) dan dibandingkan dengan kumpulan kawalan (n=44). Keputusan 
kajian mendapati, empat antiserum telah beIjaya dihasilkan dan diuji terhadap survivin 
secara immunohistokimia. Larutan penampan pemulihan antigen pH 9 adalah lebih baik 
berbanding dengan pH 6 dan optimasi telah diperolehi dengan kaedah analisis optimasi. 
Survivin didapati diekspres di dalam sel normal fetus mencit dan tikus yang aktif tetapi 
tidak pada sel normal yang telah membeza. Nilai IC50 bagi rangkaian sel MCF-7 untuk 
Doxorubixin ialah 6.0 f..lg/ml, Cyclophosphamide 171.1 f..lg/ml, 5-Fluorourasil 0.61 
f..lg/ml dim Tamoxifen 0.7 f..lg/ml. Didapati survivin diekspres kebanyakannya di 
sitoplasma. Peratus sel apoptotik meningkat dengan peningkatan dos dadah. Di 
kalangan pesakit kanser payu dara, survivin diekspres sebanyak 68.1%, p53 29.6% dan 
bcl-2 43.7%. Terdapat korelasiyang bererti (p<O.05) di antara ekspresi survivin dengan 
metastasis nodus limfa, saiz tumor, p53, bcl-2 dan kadar hidup di kalangan pesakit yang 
dikaji. Sebanyak 7% autoantibodi terhadap survivin dikesan di kalangan pesakit tetapi 
tidak pada kumpulan kawalan. Autoantibodi didapati berkorelasi dengan ekspresi 
survivin dan tahap akhir kanser. Kesimpulan kajian ialah survivin banyak diekspres 
pada sel normal yang aktif membahagi dan sel tertransformasi. Antibodi SUR -12A -CFI 
dapat menges an survivin pada tikus dan mencit. Survivin juga secara berlebihan 
diekspres di kalangan pesakit kanser payu dara dan rangkaian sel MCF-7. Survivinjuga 
mungkin boleh digunakan untuk meramal keagresifan sel tumor dan dicadangkan 
survivin boleh menjadi alat untuk membuat penilaian prognosis. 
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CHAPTER I 
INTRODUCTION 
1.1 The cell cycle 
1.1.1a The normal cell cycle 
Normal cells of multi-cellular organisms can divide as often as once or twice a 
day in vivo. The rate of cell proliferation within any population of cells depends on three 
parameters: a) the rate of cell division (Tc); (b) the fraction of cells within the 
population undergoing cell division (growth fraction), and (c) the rate of cessation of 
cell division due to terminal differentiation or cell death (Andreeff et al., 2000). 
Cellular reproduction is a cyclic process in which daughter cells are produced 
through nuclear division (mitosis) and cellular division (cytokinesis). Mitosis (M) and 
cytokinesis are part of the growth-division cycle called the cell cycle (Fig. I. 1 ). Mitosis 
lasts for about I hour, and takes a relatively small part of the total cell cycle. Interphase 
is the mitosis preparatory stage which is divided into 3 phases, Gl , S, and G2 (Fig 1.1). 
The first gap phase, G1 which lasts for about 6 hours to several days or longer, is a 
period of growth and metabolic activity following a previous mitosis (Fig. 1.1). The 
synthesis phase (S phase) follows G1 and is a period of DNA synthesis, in which the 
DNA is replicated. Another gap phase, G2 which lasts about 2 hours, follows DNA 
synthesis and precedes the next mitotic division~ Certain mature cell types do not 
continue to divide but remain in interphase (in Go). Cells that are permanently in the Go 
Some cells retain the 
ability to move from 
Go back into the cell 
cycle _ 
••• ?' 
••• 
••• 
••• 
•••• R 
•••• 
Go 
quiescence 
Survivin is 
expressed here, 
G}Mphase 
- ..... 
M 
..... 
Checkpoint by wild p53 
(Normal situation) 
G j phase 
First Gap: Cell 
Growth 
G2 
Second Gap: 
Cell Growth 
S phase: 
DNA synthesis 
Checkpoint by 
wild type p53 
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Figure 1.1: Cell cycle pathways showing its check points and regulators of a normal 
cell. M=Mitosis, G= Gap, S=Synthesis, R=Restriction (Andreef et aI., 
2000; Li et at., 1998). 
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phase are in a quiescent state and are called post-mitotic (Andreeff et al., 2000; Levine 
1997; Adam et al., 2001; Banks et al., 2000; Bartek & Lukas, 2001;Bursch et al., 2000). 
The timing and ordering of cell cycle transitions are dependent on separate 
positive and negative regulatory circuits. The regulatory circuits enforce a series of 
checkpoints, allowing passage only after completion of critical cell cycle events. Two 
classes of regulatory pathways exist, intrinsic and extrinsic. Intrinsic regulatory 
pathways are responsible for the precise ordering of the cell cycle events. Since the 
lengths of S, G2, and M phases in ma.nnnalian cells are relatively invariant, the 
transitions between these phases are controlled predominantly by intrinsic regulatory 
pathways. Extrinsic regulatory pathways function in response to environmental 
conditions or in response to detected cell cycle defects. Both types of regulatory 
pathways can use the same checkpoints (Andreeff et al., 2000; Evans &Vousden, 2001). 
When DNA is damaged by alkylating agents or by UV radiation, cells initiate a 
response that includes cell cycle arrest, apoptotic cell death, and transcriptional 
induction of genes involved in DNA repair. Normal cells in G1 phase prior to the 
restriction point (R) will arrest in GI phase upon sensing DNA damage (Fig. 1.1) 
(Andreeff et al., 2000; Budiharjo et aI., 1999; Fernandez et al., 1998; Fu et aI., 2004). 
1.1.Ib The cell cycle of tumour cell: tumour growth and cell proliferation 
Cancer is a disease of accumulation of clonally expanded cells. Tumour cell 
numbers increase, and the tumour burden accounts for the adverse effects on the host 
(Andreeff et aI., 2000). Thus, cancer is a disease of uncontrolled proliferation. The 
mechanisms that underly tumour and normal cell proliferation are very similar 
(Andreeffet al., 2000). Both bcl-2 and p53 playa role in determining tumour growth by 
their effects on apoptosis and cell proliferation (Linjawi et al., 2004). Hence, tumour 
growth is the net result of cell proliferation and cell death (Siziopikou & Schnitt, 2000). 
P53 is the guardian or the master brake in the cell cycle. When some cellular 
mechanism goes wrong, the wild p53 will stop the cell from dividing, but if the wild 
p53 is altered to a mutant p53, it can no longer stop the cell from dividing. As the 
situation.is not an abnormal control of the cell control but the cell cycle can no longer be 
controlled iffuere are genetically altered cells (Levine, 1997; Park et al., 1997; Moreno 
et ai., 2001; Nakahara et al., 1998; Shiratsuchi et al., 2002). 
1.1.2 Apoptosis 
Apoptosis or programmed cell death (PCD) is a universal and physiological 
process responsible for removing unwanted, old, damaged, and misplaced cells during 
embryonic development and tissue homeostasis (Sreedhar & Csermely, 2004; Bomer, 
2003; Andreeff et ai., 2000; Eissa et al., 1999; Strasser et al., 1997). The study of 
apoptosis has emerged from relative obscurity to become a major focus of research 
interest in many areas of medicine in the last decade (Rudin et al., 1997). 
Apoptosis is derived from Greek and refers to the dropping or falling of leaves 
from a tree (Sreedhar & Csermely, 2004). The term was introduced by Kerr et ai., 
(1972) to define the morphologic features of the apoptotic process. Some promoter and 
suppressor genes control this process (Sirvent et ai., 2004; Roninson et al., 2001). 
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1.1.2.1 The major elements of apoptosis 
Apoptosis is well characterized by distinct morphological and physiological 
changes (Sirvent et aZ., 2004). The p53 protein is also involved in both the extrinsic and 
the intrinsic pathways of apoptosis by initiating apoptosis through mitochondrial 
depolarization and sensitizing cells to inducers of apoptosis (Hofseth et aI., 2004). 
Apoptosis is induced by an array of, internal and external stimuli or signals and its 
mechanism has several common elements regardless of the ultimate biochemical 
pathways utilized (Kiechle & Zhang, 2002). Apoptosis can be divided into three phases. 
The fIrst phas~ is the initiation phase (or signalling phase), which involves the activation 
of surface death receptors (extrinsic' pathways), mainly the tumour necrosis factor 
(mF) family members, the mitochondrial pathway (intrinsic pathway) or the initiation 
of apoptosis by other stimuli (e.g., those affecting the endoplasmic reticulum (ER). The 
second is the signal transduction phase (or preparation phase), where activation of 
initiator caspases (caspase-8, caspase-9, caspase-lO, and caspase-12) and certain 
kinases/phosphatases takes place. This is followed by the execution phase (or death 
phase), which involves the activation of effector caspases (caspase-3, caspase-6, and 
caspase-7) (Fig. 1.2) (Bronchud et aI., 2000; Thornberry & Lazebnik, 1998). 
Mammals have two distinct apoptosis signalling pathways, extrinsic and 
intrinsic (Coultas & Strasser, 2003). Signalling through both the extrinsic and intrinsic 
pathways can be modulated by lAPs (inhibitor of apoptosis proteins) such as bcl-2 and 
survivin, which are highly conserved polypeptides that selectively inhibit the activation 
and functional activity of various caspases (Kaufmann & Earnshaw, 2000; Reed, 1999; 
Sanna et af., 2002; Deveraux & Reed, 1999; Campora et af., 2000; Parton et af., 2001). 
1.1.2.2 The extrinsic apoptotic pathway 
This is a receptor-linked pathway that requires the binding of a ligand to a death 
receptor on the cell surface. For example, the cytokine, tumour necrosis factor eINF), 
binds to the death receptor, 1NF receptor type 1 (TNFRI), which recruits two signal 
transducing molecules; TNFR I-associated protein with a death domain, and a Fas-
associated polypeptide containing a death domain (F ADD). This complex then binds to 
procaspase 8 to activate caspase 8, which, in turn initiates the protease cascade leading 
to apoptosis (Fig. 1.2) (Bronchud et al., 2000; Lockshin et al., 2000; Uno et al., 2002). 
,~' 
1.1.2.3 The intrinsic apoptotic pathway 
This pathway is mediated by the mitochondrial release of cytocrome c (Kiechle 
& Zhang, 2002; Pruschy et al., 2001). It is mainly activated when damaged DNA is not 
sensed and repaired by checkpoint genes. Initiation of apoptosis may occur immediately 
or it may be delayed following the DNA damage. The response mayor may not be 
dependent on the presence of the nuclear transcription factor, p53. When p53 is 
upregulated, it is activated by the phosphorylation of serine 46 by the homeodomain-
interacting protein kinase-2, and the two proteins cooperate in the activation of the p53-
dependent transcription. (Bronchud et al., 2000; Levine 1997). Proteins induced by p53 
include Bax, a bcl-2 homologous protein, which oligomerizes and fonns pores in the 
outer mitochondrial membrane, resulting in either a decrease in the inner mitochondrial 
transmembrane potential or opening of the voltage-dependant anion channel, 
releasing cytochrome c from the space between the mner and outer 
mitochondrial membranes (Heiser et al., 2004). Cytosolic cytochrome c induces the 
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Figure 1.2 : The routes of apoptosis (Reed, 2001; Bomer, 2003; Bossy-Wetzel & 
Green, 1999; Suzuki et at., 2001; Coultas & Strasser, 2003) 
7 
formation of the multi subunit apoptosome composed of apoptotic protease activating 
factor-1 (Apaf-1), procaspase 9 and either ATP or dATP. Caspase 3 then mediates the 
apoptotic cascade (Heiser et aI., 2004; Bronchud et al., 2000). lAPs of both cellular and 
viral origin have been identified to be intrinsic cellular suppressors of apoptosis that 
block the apoptotic program in response to viral infection or other forms of stresses such 
as survivin (Pruschy et al., 2001; Li & Li, 2000; Thomas, 2000; Shu et al., 1997). 
1.1.2.4 Cell morphology and physiological changes during apoptosis 
The process of apoptosis involves a cell dying in the midst of surviving cells, in 
contrast to necrosis, which involv<:;s clUsters of dying cells in an area associated with an 
inflammatory infiltrate. Apoptosis occurs as a single cell death surrounded by healthy 
cells. The morphological changes in apoptosis can be seen by light microscopy, and 
have been characterized further by electron microscopy (Archer ef- al., 2000). These 
include nuclear (chromatin) conderisation with the chromatin forming clumps that 
gather adjacent to the nuclear membrane (nuclear periphery). Furthermore, the 
cytoplasm condenses leading to cell shrinkage due to contraction of the cell and loss of 
volume, and to cell rounding due to loss of adhesion to surrounding cells and membrane 
blebbing. These bodies with condensed nuclear chromatin and, once released into the 
extra-cellular space, are rapidly ingested by phagocytic cells (Coultas & Strasser, 2003; 
Robertson et al., 2000; Wylie & Currie, 1980; Gonzalez-Campora et aI., 2000). 
The major physiological changes comprise fragmentation of nuclear DNA due 
to activation of specific endonucleases cleaving nuclear DNA into 80-200 
oligonucleosomal fragments, and the activation of caspases, resulting in partially 
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digested proteolytic protein products (Sreedhar & Csermely, 2004; Bronchud et a!., 
2000). This process produces cell breaking into several fragments of nuclei and 
cytoplasm or both nuclei and cytoplasm, known as apoptotic bodies (Sirvent et a!., 
2004). Thus, DNA fragmentation is a characteristic biochemical marker of apoptosis. 
1.1.3 Components of the apoptotic pathways 
The key elements which execute the apoptotic process have been studied 
(Bomer, 2003). Over the years, many components of the apoptotic pathways have been 
characterized:' revealing apoptosis to be a highly complex process. However, a pattern is 
emerging with a series of early events that depend on the initial stimulus, followed by a 
common pathway involving a series of cysteine proteases, the caspases. This common 
pathway ultimately results in DNA fragmentation and morphological changes associated 
with apoptosis. Mitochondria have emerged as having a central role -in the process and 
its regulation, with the bcl-2 family of proteins playing a particularly important part 
(Strasser et a!., 1997; Kaufman & Gores, 2000; King & Cidlowski, 1995). 
1.1.3.1 The caspase death proteases 
Caspase is a nomenclature referring to ICE/CED-3 cysteine proteinase family 
having a central role during cell death (Suzuki et al., 2001) and in executing the process 
of apoptosis (Fig. 1.2) (Bomer, 2003). In mammals, 14 members of the caspase family 
have been identified which cleave their substrates after aspartic acid (Asp). Activation 
of pro-caspases requires two caspases cleaved at the aspartic acid (Asp) residues 
(Strasser et al., 1997). These cleavages remove the amino-terminal pro-domain and 
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separate the large and small catalytic subunits. Once activated, caspases can process and 
activate their own subunits and other pro-caspases (Bossy-Wetzel & Green, 1999). 
Caspase activation is not reversible and leads to cell apoptosis (Gompel et aI., 2004). 
These enzymes are. minimally active m healthy cells and require further 
activation in response to apoptotic stimuli such as ionizing radiation, chemotherapeutic 
drugs, and death receptor ligands (Shi, 2002; Alarcon & Ronai et al., 2002;Pruschy et 
al., 2001). They are divided into two categories; initiator caspases and effector caspases. 
The former includes caspase-2, caspases 8- to 10, and caspase-12, which are activated in 
response to a"cell death signal, and the latter includes caspase-3, caspase-6 and caspase-
7 which transmit the signal activating the cascade that results in DNA fragmentation and 
cell death (Subsection 1.1.2.4) (Kawamura et al., 2003; Earnshaw et al., 1999). 
1.1.3.2 Cytochrome c 
Cytochrome c is a protein that is normally stored in the intermembrane space of 
mitochondria (Scorrano et al., 2003). When the cell receives an apoptotic signal, 
cytochrome c crosses the outer mitochondrial membrane and accumulates in the cytosol 
where its functions as a cofactor in the activation of caspases (Fig. 1.2) (Bossy-Wetzel 
& Green, 1999). Cytochrome c triggers a post-mitochondrial pathway forming an 
oligomeric complex of cytochrome c/ apoptotic protease activating factor-l (Apaf-
1)/caspase-9, the "apoptosome", which activates the initiator caspase-9 to subsequently 
cleave the effector caspase-3 and caspase-7 to cause nuclear fragmentation (Scorrano et 
al., 2003; Kaufmann & Earnshaw, 2000). The treatment of HeLa cells with 
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staurosporine, a potent pro-apoptotic agent, causes the rel~ase of cytochrome c from the 
mitochondria into the cytosol (Kaufmann & Earnshaw, 2000; Michalides, 1999). 
1.2 Sunrivin 
Survivin is a 16.5-kDa protein also known as AP14 or BIRC5. It is an 
intracellular protein that inhibits apoptosis and regulates cell division and belongs to the 
inhibitors of apoptosis (lAP) gene family (Verdacia et ai., 2000; Altieri, 2001). 
Members of the lAP family prevent cells from apoptosis, by inhibiting caspases (Fig. 
1.2) (Wojcik 'et ai., 2002; Yamamoto & Tanigawa, 2001). Survivin was discovered in 
1997 by hybridization screening of a' human genomic library with the cDNA of the 
effector cell protease receptor-l (EPR-l) (Ambrosini et ai., 1997). The survivin gene 
spans 15 kb, and is located on chromosome 17 t band q25. Survivin has an unusual 
relationship to EPR-1 in that its sequence is complementary to and in the reverse 
orientation of EPR -1. The coding strand of survivin contains an open reading frame of 
426 nucleotides, and encodes a protein of 142 amino acids (Chiou et ai., 2003). 
Survivin over-expression in vivo increases cell resistance to apoptosis (Chiou et 
aI., 2003). This conclusion has been proven by the study of Grossman et aI., (2001a) 
when transgenic expression of survivin in epidermal keratinocytes significantly reduced 
the number of apoptotic cells in the epidermis following exposure to ultraviolet (UV) 
irradiation. Conversely, inhibition of survivin expression in vitro, by treatment with 
antisense survivin oligonucleotide, increased the susceptibility of HeLa cells to 
receptor-mediated apoptosis, and the human neural tumour cell lines to induced 
apoptosis, MSN and TC620 (Shankar et aI., 2001). 
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Survivin appears to have an important role in regulating apoptosis at the cell 
cycle checkpoint(s). Its expression is highly cell cycle-regulated, and is detectable in the 
nucleus selectively at the G21M phase (Li et aI., 1998). Transcription of survivin has 
been shown to be directly repressed by wild-type p53, another cell cycle checkpoint-
regulating protein that induces apoptosis (Mirza et aI., 2002). When acute 
lymphoblastic leukemia cells are treated with doxorubicin, which causes accumulation 
of wild type p53, the result is a dramatic down-regulation of survivin, depletion of cells 
in the G2/M phase of the cell cycle, and increased apoptosis (Zhou et aI., 2002). 
In ad<Iition, SurvlVlll appears to be important for cell cycle progression. 
Disruption of survivin by antisense targeting HeLa cells results in spontaneous 
apoptosis and aberrant mitosis, as well as an increase in caspase-3 activity at mitosis. 
Disruption of survivin in cell lines by both antisense targeting and survivin antibodies 
also induces polyploidy and aneuploidy as a result of cytokinesis failure and the 
premature onset of anaphase. In vivo, survivin is also required for cell division. 
Homozygous knockout of the survivin gene in mouse embryonic stem cells resulted in 
disrupted microtubule formation and polyploidy during development, which culminated 
in early embryonic lethality (Uren et aI., 2000). 
1.2.1 Structure and function of survivin 
The structure of human SurvlVlll, as determined by X-ray crystallography, 
reveals the presence of an amino-terminal globular zinc finger domain, which includes 
the BIR motif, and a long carboxy-terminal helix separated by a short linker segment, 
important for dimerization (Rodriguez et aI., 2002). The structure of survivin is 
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intimately linked with its function as an inhibitor of apoptosis. The amino terminal 
portion of survivin consists of three alpha helices (residues 14-21, 31-41, 68-80) and 3 
beta-sheets (residues 43-45, 55-58, 61 ~64). which closely resemble the BIR domain that 
is conserved in the lAP family (Fig 1.3). The BIR domains of lAP family members are 
involved in the function of these proteins as inhibitors of apoptosis (Verdecia et al., 
2000). A mutation in the BIR domain, T34A, which inhibits phosphorylation of 
survivin by p34-cyclin Bl, abrogates the ability of survivin to inhibit apoptosis (Chiou 
et al., 2003). 
Three -different isoforms of this protein have been identified: survivin (142 aa), 
.,i;' 
survivin-2B (165 aa) and survivin-~Ex3 (137 aa) (Mahotka et al., 1999). Sur,vivin and 
survivin-2B are located in the cytoplasm whereas survivin-~Ex3 is located in the 
nucleus. Another isoform was reported in 2004 by Badran et al. 2004 designated as 
survivin 3B (120 aa) in human adenocarcinoma cell lines. It is likely that survivin-3B 
possesses anti-apoptotic activity. Survivin-~Ex3 has anti.;apoptotic properties whilst 
survivin-2B with markedly reduced anti-apoptotic properties (Badran et aI., 2004). It 
was reported that the localization in distinct cellular compartments of different nuc1ear-
cytoplasmic variants might constitute a regulatory mechanism for the activity of 
different splice variants of survivin. The different isoforms of survivin is believed to 
playa distinct role in cancer and therefore that such a role may be partially determined 
by their differential nuclear-cytoplasmic transport and localization (Rodriguez et at., 
2002). 
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Figure 1.3: The overall architecture of human survivin. a, Ribbon representation of the 
survivin dimer. The Zn 2+ ion is shown as a shaded sphere. Coordination 
bonds are shown as dotted orange spheres. One monomer is blue; the other is 
rose. b, Orthogonal view of the ribbon representation shown in (a). c, 
Perspective and close up view of the Zn2+ binding site on one survivin 
monomer. The depicted orientation corresponds to that pictured in (a). 
(Verdecia et al., 2000) 
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1.2.2 The mechanism of survivin inhibition of apoptosis 
Survivin is identified as an intrinsic cellular regulator that plays an important 
role in the suppression of apoptosis by either directly or indirectly inhibiting the activity 
of caspases (Hikita et aI., 2002; Badran et al., 2003; Badran et al., 2004; Bao et aI., 
2002; Honda et at., 2003; Kuttler et aI., 2002; Li et al., 1998; Song et aI., 2004; Song et 
aI., 2003). Several lAP family members have been shown to suppress apoptosis by 
direct inhibition of caspases via the BlR domains. The structure of survivin has been 
compared to another lAP family member, XIAP, which contains three BlR domains 
(Tran et at., 1'999; Otaki et at., 2000; Shinozawa et al., 2000; Sohn et at., 2003). XlAP 
inhibits caspase-3 and caspase-7 via a'linker region between the first two domains, and 
also binds to and inhibits caspase-9 through its third BlR domain (BIR3). The BIR 
domain of survivin appears to be closely related in its three dimensional structure to the 
BIR3 domain of XlAP, suggesting the possibility ·,that survivin binds caspase-9. 
Survivin has a capability to bind to caspases and modulate their functions (Kawamura et 
aI., 2003; Sandler et al., 2002; Sarela et aI., 2001; Wheatley et at., 2001; Mahotka et al., 
2002; Komacker et aI., 2001; Krieg et aI., 2002). The interaction between survivin and 
caspase-9, and the functional implication of this interaction have been studied through 
mutagenesis. Loss of phosphorylation at threonine 34 on the T34A mutant of survivin 
results in the dissociation of an immunoprecipitable survivin-caspase-9 complex on the 
mitotic apparatus, allowing caspase-9 dependent apoptosis to occur (Chiou et aI., 2003; 
Wall et at., 2003; Li et at., 1999; Lu et aI., 2004; Fortugno et at., 2003). 
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1.2.3 The role of survivin in cell division 
Recent reports demonstrated how survivin may act in regulating cell division. 
During the cell cycle, survivin IS first detected on the centromere at 
prophase/metaphase. It IS also present III the spindle midzone during 
anaphase/telophase, but is no longer detected by the end of telophase (Li et aI., 1998: 
Uren et at., 2000). Furthermore, it was indicated that survivin remains localized in 
kinetochores until metaphase, then in the spindle midzone during anaphase, and in the 
cleavage plane during telophase. The kinetochore is a DNA-protein complex that 
assembles on'the centromere and its required for attachment of the microtubules during 
mitosis (Uren et at., 2000). These localization patterns resemble those of the inner 
centromere proteins (INCENP), TD-60, and Aurora B, which are known as 
chromosomal passenger proteins. Thus, based on its localization during the cell cycle, it 
has been postulated that survivin may be an additional chromosomal-passenger protein. 
These four proteins are the only mammalian passenger proteins known to date, which 
are carried on the chromosomes to the center of the cell at metaphase, in the plane of the 
future cleavage furrow, and are important for cytokinesis and chromosomal movements 
during cell division (Chiou et at., 2003). It was concluded that the primary role of 
survivin is to regulate chromosome segregation and cytokinesis (Uren et al., 2001) 
1.2.4 Survivin expression in cell lines, and in embryonic, fetal, and normal adult 
tissues 
The regulation of a'poptosis is critical for normal embryonic development and for 
homeostasis in adult tissues (Grossman et aI., 2001b). In animals, survivin is strongly 
expressed in embryonic and fetal organs, but is undytectable in most terminally 
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differentiated normal tissues (Mori et al., 2002). Uren et al., (2001) found that survivin 
is expressed in mouse embryos. In the mouse model, survivin was found to be elevated 
at the G2/M phase of the cell cycle during liver regeneration (Deguchi et al., 2002). Kim 
et al., (2003) reported that survivin is strongly expressed at the bottom of mouse 
embryonic intestinal crypts. At the protein level, survivin was also detected during all 
stages of early embryos of mice (Kawamura et al., 2003; laskoll et al., 2001). 
The expression of survivin in normal human adult tissues, appeared only in a 
few published reports, contrary to numerous reports examining the role of survivin in 
cancer (Chio~ et al., 2003). However, its expression has been reported in a few normal 
growing adult human tissues, including thymus (Kobayashi et al., 2002), colonic 
mucosa (Gianani et al., 2001), placenta (Shiozaki et al., 2003; Lehner et al., 2001), bone 
marrow (Altieri & Marchisio, 1999), and keratinocytes of the basal layer of the skin 
(Grossman et al., 2001a; O'Driscoll et al., 2003; Chiodino et al., 1999). 
During human development, survivin is expressed in the fetal lung, heart, liver, 
kidney, and gastrointestinal tract, and in fetal tissues where apoptosis occurs, such as the 
stern cell layers of stratified epithelia, endocrine glands, pancreas and thymic medulla. 
In all of these studies, survivin was not found in normal adult tissues. These findings 
suggest that the regulation of cell division and the anti-apoptosis functions of survivin 
are important not only during early development, but also during cancer progression 
(Chiou et a/. , 2003). 
In cell lines, it was reported that survivin was expressed in HeLa cells (Uren et 
al., 2001), human breast cancer cell line, MCF-7 (Tanaka et al., 2004), melanoma cell 
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lines (Ambrosini et al., 1998; Grossman et al., 1999), a lung adenocarcinoma cell line 
(Olie et al., 2000), neuroblastoma and oligodendroglioma cell lines (Shankar et al., 
2001), a murine thymic lymphoma cell line (Kanwar et al, 2001) and a colorectal 
cancer cell line (Me sri et al., 2001), human colon adenocarcinoma cells, HT29 
(Yamamoto et al., 2002). 
1.2.5 Survivin and cancer 
One of the most significant features of survivin is its differential distribution in 
cancer comp~ed to normal tissue. Over-expression of survivin has been demonstrated 
in tumours of the lung, breast (Zhang it aI., 2004), esophagus, pancreas, bladder, uterus, 
cervix, ovary (Mei et aI., 2001; Tarkowski et al, 2001; Tao et aI., 2004), large-cell non-
Hodgkin's lymphoma, leukemias (Schlette et aI., 2002; Mori et al., 2002; Carter et aI., 
2001; Carter et al, 2003), neuroblastomas, melanomas, gastric (Li et al, 2004; Lu et al., 
1998; Yu et al., 2002), colon (Sarela, et al., 2000; Sarela et aI., 2001; Yang et al., 2004), 
stomach, liver (Chiou et al., 2003), oral (Muzio et aI., 2004; Muzio et aI., 2003; Muzio 
et al., 2001), thyroid (Sugawara et al., 2002), and in laryngeal squamous cell (Dong et 
al., 2002). 
Despite its role in mitosis, it is clear that the over-expression of survivin in 
cancer does not simply reflect the presence of a higher number of proliferating cells. In 
melanoma, survivin expression was indistinguishable in cases with low or high mitotic 
index. In addition, the fact that survivin is typically observed in nearly all tumour cells, 
and not just in the mitotic fraction, suggests that expression of the survivin gene is 
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Table 1.1 : Meta analysis of survivin expression in cancers in published reports 
Authors 
Li et. al., (2004) 
Fields et al . ., (2004) 
Zhang et al." (2004) 
Kayaselcuk et al..,(2004) 
Yao et al." (2004) 
Kennedy et al . .,(2003) 
Kawamura et al., ,(2003) 
Kobayashi et al.,(2002) 
Ikehara et al.,,(2002) 
Mori et al.,,(2002) 
Dong et al.,,(2002) 
Hattori et at." (2001) 
Mei et al.,,(2001) 
Lehner et al." (2001) 
Tanaka et aI., (2000) 
Lu et al.,,(1998) 
Method of 
detections 
Immunohistochemistry 
(IRC) 
mc 
IHC 
mc 
mc 
IHe 
RT-PCR&IRC 
IRC, RT-PCR, flow 
cytometry 
IRC 
ReversePCR 
IRC 
RT-PCR 
IHC 
IHC 
IHC 
IHC 
Subj ects/locations 
Gastric carcinoma (n=80), China 
Hepatocellular carcinoma (n=72) 
Breast carcinoma (n=119), China 
Breast carcinoma (n=43), Turkey 
Gastric adenocarcinoma (n=120), China 
Primary breast carcinoma (n=293), 
Dublin, Ireland 
9 weeks mouse embryos 
Human tymocytes, Japan . 
Small adenocarcinoma of lung 
(n=79), Japan 
Leukemia (n=31), Japan 
Laryngeal squamous cell 
carcinoma(LSCC), (n=102), Japan 
Epithelial ovarian cancer (n=43), 
Japan 
Cervical carcinoma (n=59), China 
Archival formalin-fixed human 
placenta tissues (n=25) 
Breast carcinoma (n=167) 
Gastric carcinoma (n=174), Japan 
Findings/conclusions 
Survivin (SUR) expression was 76%, no expression in adjacent normal tissues, +ve 
expression pf.SUR correlated with worse histological grades and pathological grades, 
poor prognosis. SUR inhibit apoptosis of tumor cells. 
SUR expression was 43%, SUR correlated with histological grade & stage, nuclear 
expression correlated with poor prognosis. 
SUR expression was '72.3%, correlated with poor prognosis. 
SUR +ve correlated with Bcl-2 but was not correlated with p53, bax, cerbB-2, estrogen 
& progestron, clinicopatholohgical factors (grade, stage and mitotic index). 
SUR expression was 49.17% in cytoplasma of carcinoma cells. 
SUR expression was 60%, 31 % nuclear staining, 13% cytoplasmic, 16% both nuclear& 
cyctoplasmic staining. Nuclear expression is most common and is an independent 
prognostic indicator of good prognosis. 
SUR protects embryo from apoptosis by inhibiting apoptotic pathway 
involving caspases. 
SUR play an important role in the T-ceII development in the human thymus. 
SUR has a positive correlation with Bcl-2 and CD69. 
SUR expression was 57%, correlated with venous invasion, worse overall 
survival, poor prognosis. 
SUR expression was 54% in acute myelocytic leukemia, 69% in acute 
lymphocyctic leukemia, no expression. in normal bone marrow, provide 
prognostic information. 
SUR expression was 65.7%, associated with tumor site, poor differentiation, 
tumor size, lymph node metastasis & advanced stage, unfavorable 
clinicopathological factors. 
SUR expression was 86%, 
SUR expression was 69.5%, strongly associated with Bcl-2. 
SUR expression was 68% 
SUR expression was 70.7% 
SUR expression was 34.5%, coexpression with Bcl-2 and segregated with p53 
positive. 
deregulated in cancer, albeit still retaining cell-cycle periodicity in mitosis (Chiou et at., 
2003; Daidone et at., 2001; Endoh et at., 2001; Frost et al., 2002; Gu & Lin, 2004). 
In certain cancers, two types of molecular abnormalities have been reported that 
might contribute to aberrant survivin expression. Gain of chromosome 17q is the most 
common genetic abnormality in neuroblastoma, where amplification of the survivin 
locus on 17q25 has been detected by fluorescence in situ hybridization (Chiou et al., 
2003; Takai et aI., 2002). In addition, survivin exonl sequences are largely silenced by 
methylation in normal ovaries, but become de-methylated, and thus trancriptionally 
active, in most ovarian cancers, leading to the over-expression of survivin (Hattori et al., 
2001). However, given the widespread survivin over-expression in many types of 
cancer, it is plausible that multiple oncogenic signalling pathways might converge on 
the reactivation of the survivin gene in neoplasia (Chiou et al., 2003). 
The role of SUfVIVill ill many cancers has been reported ill numerous 
publications, but little has been published about the role of survivin in breast cancer. A 
few reports have shown the expression of survivin in breast cancer ranging from 60% to 
72.% (Zhang et aI., 2004; Kennedy et aI., 2003; Tanaka et aI., 2000). 
1.2.6 Clinical significance of survivin 
Recently, survivin has emerged as a diagnostic and prognostic marker and a 
potential drug target because it is predominantly overexpressed in most cancer types. 
The role of survivin in the inhibition of apoptosis in breast cancer has not been clearly 
established. Furthermore, only a few reports have highlighted the clinical significance of 
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survivin. Further investigations of survivin during tumour growth and progression may 
yield important insights into its functional role(s) in carcinogenesis and allow the 
development of important therapeutic strategies for combating cancer. 
1.2.6.1 Prognostic value of survivin in cancer 
Assessment of prognosis is important in patients with malignancies because its 
results serve to separate a large heterogeneous population into smaller populations with 
more concisely predictable outcome (Hayes, 2000). In the majority of neoplasms 
investigated f~r survivin expression including breast, lung, colorectal, gastric, liver, 
bladder and kidney cancers, neuroblastoma, gliomas, soft tissue sarcomas and 
hematological malignancies, high levels of the lAP proteins were predictive of tumour 
progression, either in terms of disease-free survival or overall survival, thus providing 
prognostically relevant information (Zaffaroni & Daidone 2002; Altieri 2001; Altieri & 
Marchisio 1999). 
1.2.6.2 Survivin as a therapeutic target in cancer 
Two general considerations make survivin an attractive therapeutic target in 
cancer: it is selectively expressed in tumour cells and it is required for their viability 
(Chiou et al., 2003; Altieri, 2003b; Ueda et al., 2002; Sasaki et al., 2002; Poetker, 2002; 
Pizem et al., 2004; Iurlaro et al., 2004; Guan et al., 2004). Results obtained by different 
studies aimed at targeting survivin by means of different approaches demonstrated that 
inhibition of this cell survival factor promotes some favourable biological effects 
(Zaffaroni & Daidone 2002; Altieri, 2003a; Altieri 2004; Tsurama et al., 2004). 
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There are several therapeutic strategies targeted to survivin including the use of 
antisense oligonucleotides; natural antisense (EPR-l eDNA), oligonucleotide 4003, and 
oligonucleotides 903 and 904 (Ambrosini et ai., 1998; Grossman et ai., 1999; Olie et 
aI., 2000; Shankar et ai., 2001), dominant negative mutants: Cys 84 -7 Ala, Thr 34 -7 
Ala, and Cys 84 -7 Ala (Grosman et ai., 1999; Grossman et ai., 2001a; Mesri et ai., 
200lb; Kanwar et aI., 2001), and ribozymes (hammerhead ribozymes) (Pennati et ai., 
2002). The biological effects in vitro and in vivo using these therapeutic strategies 
demonstrated as decrease in cell proliferation, an increased spontaneous apoptosis and 
an enhanced efficacy of several types of conventional treatments including 
chemotherapy', radiotherapy and immunotherapy (Zaffaroni & Daidone 2002). 
1.3 Bcl-2 
1.3.1 Structure and biological functions of bcl-2 
B-ceU lymphoma-2 protein (Bcl-2) is the first known regulator of cell death 
(Heiser et aI., 2004). The bcl-2 family proteins are important regulators of apoptosis in 
mammalian cells (Schinzel et aI., 2004). Bcl-2 is an anti-apoptotic protein (Townsend et 
ai., 2002; Giatromanolaki et ai., 2001) and is a proto-oncogone (Formby et aI., 1999; 
Strasser et ai., 1997) that resides on the cytoplasmic face of the mitochondrial outer 
membrane, in the endoplasmic reticulum and in the nuclear envelope (Mullauer et ai., 
2001; Robertson et ai., 2000; Schinzel et aI., 2004). Bcl-2 is an acronym for the B-cell 
lymphomalleukemia-2 gene which was identified at the site of the t(14;18) 
chromosomal translocation, occurring in 85% of diffused B-cel1lymphomas (Joosens et 
ai., 1998; Strasser et aI., 1997). 
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The bcl-2 inhibits apoptosis (Eissa et al., 1999) by blocking the release of 
cytochrome c from mitochondria, thereby preventing Apaf-I (apoptotic protease-
activating factor-I) and consecutive caspase activation (Fig. 1.2). The bcl-2 may also 
inhibit apoptosis by binding to the pro-apoptotic molecules Bax and bcl-xs (Mullauer et 
al.,200I). 
. A number of proteins that are structurally related to bcl-2 (Bcl-2 protein family) 
have been discovered in mammals, birds, frogs, nematodes and viruses and can be sub-
divided into two groups. The first group includes those that inhibit apoptosis 
(mammalian 13cLxL' Bcl-w, AI, Mcl-I, nematode Ced-9, adenovirus E1BI9kD, Epstein 
Barr Virus (EBV) BHRFI, African 'Swine Fever Virus LMW5-HL, Human Herpes 
Virus 8 KSBcl-2 and Herpes Virus Saimiri ORF16). The second group includes those 
that enhance apoptosis (Bax, Bc1-xs the product of alternative splice variant of the bc1-x 
gene, Bad, Bak, BiklNbk, Bid and Harakiri (Strasser et al., 1997). The bc1-2 family of 
proteins appears to be involved in either enhancing or opposing the apoptotic process. 
In most situations, the mitochondria act as focal points in the apoptotic pathway 
and provide convenient positions for regulatory molecules to intervene. In cell free 
systems, nuclear condensation and DNA fragmentation were found to be dependent on 
the presence of mitochondria and inhibited by bcl-2 (Heiser et at., 2004). 
Bcl-2 plays a crucial role in maintaining the viability of cells that are meant to be 
long-lived such as peripheral lymphocytes (Strasser et at., 1997). The involvement of 
bcl-2 in apoptosis was first seen indirectly when it was noted to prolong cell survival. 
Immature pre-B cells dependent on IL-3 for survival in culture were noted to persist 
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despite IL-3 withdrawal when the cells were transfected with bcl-2, an effect that 
seemed to occur without cell proliferation. This persistence was later shown to be due to 
the ability ofbcl-2 to block apoptosis (Bossy-Wetzel & Green, 1999). 
The bcl-2 family of proteins is also involved in embryogenesis where it controls 
developmentally programmed cell death during tissue differentiation. After birth, bcl-2 
and its relatives play critical roles in regulating programmed cell death in the 
haematopoietic system, tissue homeostasis and mammary gland involution (Coultas & 
Strasser, 2003). 
1.3.2 Bcl-2 and its role in breast cancer 
In normal breast, bcl-2 is expressed in the non-pregnant and non-involuting 
mammary epithelium. Bcl-2 expression has previously been reported in normal breast 
ductal cells where it is supposed to be involved in the hormonal regulation of 
hyperplasia and involution (Vetrani et al., 1995). Bcl-2 is thought to be expressed 
through hormone-dependent pathways (Ioachim ef aI., 2000; Vetrani et aI., 1995) such 
as estrogen and progesterone (park ef al., 2002). 
The exact mechanism and the effect of the down regulation of bcl-2 expression 
on breast cancer cells are not clearly defined (Park ef aI., 2002). In breast cancer, bcl-2 
expression appears to be inversely correlated with the presence of p53 mutations in its 
pathways (Joosens ef al., 1998; EI-Ahmady et a!., 2002; Takei et aI., 1999; Van-Slooten 
et aI., 1998). 
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